<img width="250" height="167" src="https://www.leaprate.com/wp-content/uploads/2023/08/FIN-LP-Intercontinental-Exchange-4925964408-iStock-462756183-250×167.jpg" c
<p>Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT)
Leave a Comment